Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419690 | 0.90 | ERN1 (0.58) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL28311710 | 0.84 | ERN1 (0.47) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL12813802 | 0.84 | ERN1 (0.47) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL29785434 | 0.84 | ERN1 (0.47) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL24236790 | 0.82 | ERN1 (0.50) | ERN1 | |
| SCHEMBL29467330 | 0.82 | ALOX5 (0.49) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL187267 | 0.82 | ALOX5 (0.49) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL29467329 | 0.82 | ALOX5 (0.49) | ERN1SMN1; SMN2KDM4EMEN1USP2 | |
| SCHEMBL10977200 | 0.82 | ERN1 (0.46) | ERN1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL875823 | 0.81 | ERN1 (0.58) | ERN1SMN1; SMN2KDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507717-B2 | Production of substituted phenylene aromatic diesters | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-08-13 | — | — | US | claimed |
| EP-2373604-A2 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | Dow Global Technologies LLC (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010078512-A2 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100174105-A1 | Production of Substituted Phenylene Aromatic Diesters | W.R. GRACE & CO.-CONN. | 2010-07-08 | — | — | US | claimed |
| US-11260379-B2 | Catalysts and methods for epoxide-based polymerizations | CORNELL UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200384450-A1 | CATALYSTS AND METHODS FOR EPOXIDE-BASED POLYMERIZATIONS | CORNELL UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| US-20200384450-A1 | CATALYSTS AND METHODS FOR EPOXIDE-BASED POLYMERIZATIONS | CORNELL UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| US-20200339502-A1 | COMPOUNDS FOR USE IN THE ELIMINATION OF PLURIPOTENT STEM CELLS | UNIVERSITÄT ZU KÖLN (DE) | 2020-10-29 | — | — | US | disclosed |
| US-9795549-B2 | 1,2-alkane polyol-containing composition | OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20160045414-A1 | 1,2-ALKANE POLYOL-CONTAINING COMPOSITION | OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2985017-A1 | 1,2-ALKANE POLYOL-CONTAINING COMPOSITION | Osaka Organic Chemical Ind., Ltd. (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-1995021172-A1 | PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-08-10 | — | — | WO | disclosed |
| US-4436659-A | DYEING POLYAMIDS, AZO DYES | CIBA-GEIGY CORPORATION (US) | 1984-03-13 | — | — | US | disclosed |
| US-4318849-A | COPPER, NICKEL, CHROMIUM OR COBALT COMPLEXES OF AZO OR AZO-METHINE DYES | CIBA-GEIGY CORPORATION (US) | 1982-03-09 | — | — | US | disclosed |
| US-4312887-A | 2-Hydroxylaminomethyl phenols | ABBOTT LABORATORIES (US) | 1982-01-26 | — | — | US | disclosed |
| US-4273940-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1981-06-16 | — | — | US | disclosed |
| US-4215042-A | PRINTING AND DYEING OF POLYAMIDES; COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1980-07-29 | — | — | US | disclosed |
| EP-0011654-A1 | Nuclear substituted 2-hydroxymethane-sulfamic acids and pharmaceutical compositions | MERCK & CO. INC. (US) | 1980-06-11 | — | — | EP | disclosed |
| US-4159279-A | SALURETIC-DIURETICS, DERMATOLOGICAL DISORDERS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174105-A1 | Production of Substituted Phenylene Aromatic Diesters | DDT, COMT, DDC | ERN1 1972/4885SMN1; SMN2 4239/4885KDM4E 113/4885 |
| US-20200339502-A1 | COMPOUNDS FOR USE IN THE ELIMINATION OF PLURIPOTENT STEM CELLS | ALPG, RARB, RARG | ERN1 3405/4885SMN1; SMN2 1033/4885KDM4E 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.